LIPELLA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.442 USD | -3.50% |
|
-1.71% | -56.67% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 5.92 | 3.362 | - | - |
| Enterprise Value (EV) 1 | 5.92 | 3.362 | 3.362 | 3.362 |
| P/E ratio | -1.32 x | -1.16 x | -1.58 x | -1.43 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -0.99 x | -0.66 x | -0.44 x |
| FCF Yield | - | -101% | -152% | -228% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,804 | 7,606 | - | - |
| Reference price 2 | 1.020 | 0.4420 | 0.4420 | 0.4420 |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -4.577 | -6.661 | -9.992 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.551 | -6.661 | -9.992 |
| Net income 1 | -4.619 | -4.551 | -6.661 | -9.992 |
| Net margin | - | - | - | - |
| EPS 2 | -0.7700 | -0.3800 | -0.2800 | -0.3100 |
| Free Cash Flow 1 | - | -3.4 | -5.1 | -7.65 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -1.026 | -1.081 | -1.252 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -1.026 | -1.081 | -1.252 |
| Net income 1 | -1.192 | -1.026 | -1.081 | -1.252 |
| Net margin | - | - | - | - |
| EPS 2 | -0.1600 | -0.1300 | -0.0700 | -0.0800 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -3.4 | -5.1 | -7.65 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.442
USD
Average target price
2
USD
Spread / Average Target
+352.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.67% | 3.36M | |
| +15.58% | 121B | |
| +16.60% | 110B | |
| +18.08% | 25.98B | |
| -24.33% | 19.27B | |
| -18.56% | 15.99B | |
| -17.95% | 15.66B | |
| -48.32% | 14.5B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
- Stock Market
- Equities
- LIPO Stock
- Financials Lipella Pharmaceuticals Inc.
